| |  Online-Ressource |
|---|
| Verfasst von: | Thomann, Anne K. [VerfasserIn]  |
|---|
| | Schulte, Lucas-Alexander [VerfasserIn] |
|---|
| | Globig, Anna-Maria [VerfasserIn] |
|---|
| | Hoffmann, Peter [VerfasserIn] |
|---|
| | Klag, Thomas-Matthias [VerfasserIn] |
|---|
| | Itzel, Timo [VerfasserIn] |
|---|
| | Teufel, Andreas [VerfasserIn] |
|---|
| | Schreiner, Rupert [VerfasserIn] |
|---|
| | Scheffe, Nina [VerfasserIn] |
|---|
| | Ebert, Matthias [VerfasserIn] |
|---|
| | Wehkamp, Jan [VerfasserIn] |
|---|
| | Gauss, Annika [VerfasserIn] |
|---|
| | Hasselblatt, Peter [VerfasserIn] |
|---|
| | Klaus, Jochen [VerfasserIn] |
|---|
| | Reindl, Wolfgang [VerfasserIn] |
|---|
| Titel: | Ustekinumab serum concentrations are associated with clinical outcomes in Crohn’s disease |
|---|
| Titelzusatz: | a regional multi-center pilot study |
|---|
| Verf.angabe: | Anne Kerstin Thomann, Lucas-Alexander Schulte, Anna-Maria Globig, Peter Hoffmann, Thomas Klag, Timo Itzel, Andreas Teufel, Rupert Schreiner, Nina Scheffe, Matthias Philip Ebert, Jan Wehkamp, Annika Gauss, Peter Hasselblatt, Jochen Klaus, Wolfgang Reindl |
|---|
| E-Jahr: | 2020 |
|---|
| Jahr: | February 11, 2020 |
|---|
| Umfang: | 6 S. |
|---|
| Fussnoten: | Gesehen am 10.06.2020 |
|---|
| Titel Quelle: | Enthalten in: Zeitschrift für Gastroenterologie |
|---|
| Ort Quelle: | Stuttgart [u.a.] : Thieme, 1997 |
|---|
| Jahr Quelle: | 2020 |
|---|
| Band/Heft Quelle: | 58(2020), 05, Seite 439-444 |
|---|
| ISSN Quelle: | 1439-7803 |
|---|
| Abstract: | <p> <b>Background and aim</b> The role of therapeutic drug monitoring (TDM) in ustekinumab (UST) therapy for Crohn’s disease (CD) has not been established, as only few studies have analyzed the relationship between UST serum concentrations and clinical outcome. In this pilot study, we retrospectively examined the potential of UST-concentrations (cUST) 8 weeks after induction (cUSTw8) to predict clinical response at week 16.</p> <p> <b>Methods</b> Serum samples and clinical data from patients (n = 72) with moderate to severely active CD who received intravenous induction with UST were retrospectively analyzed. cUST were quantitated using liquid chromatography-tandem mass spectrometry (LC-MSMS). A receiver-operating characteristic (ROC) curve and area under ROC curve (AUROC) was computed to analyze the predictive potential of cUSTw8 for clinical response at week 16 and to determine the minimal therapeutic UST trough concentration.</p> <p> <b>Results</b> Forty-four patients (61 %) achieved clinical response to UST therapy at week 16. cUSTw8 was moderately effective to predict clinical response with a minimal therapeutic cUSTw8 of 2.0 mg/l (AUC 0.72, p = 0.001).</p> <p> <b>Conclusion</b> Trough concentrations of UST 8 weeks after induction predict clinical response to therapy in week 16 with moderate sensitivity and specificity. TDM using LC-MSMS could prove beneficial in personalized UST therapy of patients with CD by identifying individuals with subtherapeutic concentrations who might benefit from dose escalation.</p> |
|---|
| DOI: | doi:10.1055/a-1088-1461 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1055/a-1088-1461 |
|---|
| | Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1088-1461 |
|---|
| | DOI: https://doi.org/10.1055/a-1088-1461 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 1700358723 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Ustekinumab serum concentrations are associated with clinical outcomes in Crohn’s disease / Thomann, Anne K. [VerfasserIn]; February 11, 2020 (Online-Ressource)
